Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Pharmacology|June 13, 2022
Treatment with Living Drugs: Pharmaceutical Aspects of CAR T CellsAstrid Holzinger, Hinrich AbkenRecent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|September 2, 2019
Advances and Challenges of CAR T Cells in Clinical TrialsAstrid Holzinger, Hinrich AbkenHemasphere|November 15, 2019
CAR T Cells: A Snapshot on the Growing Options to Design a CARAstrid Holzinger, Hinrich AbkenMolecular Therapy : the Journal of the American Society of Gene Therapy|January 16, 2025
The risk of reactivity against healthy tissues: Novel CARs demand testing for overlooked binding propertiesAstrid Holzinger, Florian Weber, Hinrich AbkenCancer Immunology, Immunotherapy : CII|September 11, 2016
The growing world of CAR T cell trials: a systematic reviewAstrid Holzinger, Markus Barden, Hinrich AbkenInnere Medizin (Heidelberg, Germany)|June 25, 2025
[CAR T cells in solid tumors: resistance mechanisms]Markus Barden, Astrid Holzinger, Hinrich AbkenHuman Gene Therapy|April 6, 2018
CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical ApplicationsUlrike Köhl, Stanislava Arsenieva, Astrid Holzinger, et al.Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapyTobias Riet, Astrid Holzinger, Jan Dörrie, et al.Cells|December 11, 2022
CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine LoopDennis Christoph Harrer, Charlotte Schenkel, Valerie Bezler, et al.Frontiers in Immunology|February 23, 2023
CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activationMarkus Barden, Astrid Holzinger, Lukas Velas, et al.Pageof 2